Jon E. Angell

Array ( [id] => 13841203 [patent_doc_number] => 20190024086 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-01-24 [patent_title] => METHODS AND COMPOSITIONS FOR MODULATING GENE EXPRESSION [patent_app_type] => utility [patent_app_number] => 16/155688 [patent_app_country] => US [patent_app_date] => 2018-10-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 66217 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -42 [patent_words_short_claim] => 44 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16155688 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14778611 [patent_doc_number] => 20190264203 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-29 [patent_title] => GLYCOCONJUGATES OF RNA INTERFERENCE AGENTS [patent_app_type] => utility [patent_app_number] => 16/152516 [patent_app_country] => US [patent_app_date] => 2018-10-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20567 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16152516 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14464733 [patent_doc_number] => 20190184006 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-06-20 [patent_title] => ENHANCED IMMUNOGENICITY OF mRNA WITH CO-ENCODED ADJUVANT SEQUENCES [patent_app_type] => utility [patent_app_number] => 16/152096 [patent_app_country] => US [patent_app_date] => 2018-10-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19432 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16152096 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20665061 [patent_doc_number] => 12606823 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-04-21 [patent_title] => Modified CPF1 guide RNA [patent_app_type] => utility [patent_app_number] => 16/753293 [patent_app_country] => US [patent_app_date] => 2018-10-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 31 [patent_figures_cnt] => 41 [patent_no_of_words] => 8098 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 90 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16753293 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13837277 [patent_doc_number] => 20190022123 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-01-24 [patent_title] => RNAi Therapy for Hepatitis B Virus Infection [patent_app_type] => utility [patent_app_number] => 16/148249 [patent_app_country] => US [patent_app_date] => 2018-10-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26985 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16148249 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16177232 [patent_doc_number] => 20200224200 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-16 [patent_title] => MODULATION OF IMMUNE RESPONSE THROUGH STIMULATOR OF INTERFERON GENES [patent_app_type] => utility [patent_app_number] => 16/650614 [patent_app_country] => US [patent_app_date] => 2018-09-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21749 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -37 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16650614 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16253800 [patent_doc_number] => 20200263174 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-20 [patent_title] => RNA molecules [patent_app_type] => utility [patent_app_number] => 16/647241 [patent_app_country] => US [patent_app_date] => 2018-09-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 61521 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -93 [patent_words_short_claim] => 263 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16647241 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16298051 [patent_doc_number] => 20200283774 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-10 [patent_title] => APTAMER AGAINST M.TB MPT51 AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/758185 [patent_app_country] => US [patent_app_date] => 2018-09-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6773 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 59 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16758185 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13987195 [patent_doc_number] => 20190062755 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-02-28 [patent_title] => MODULATION OF ANGIOPOIETIN-LIKE 3 EXPRESSION [patent_app_type] => utility [patent_app_number] => 16/125584 [patent_app_country] => US [patent_app_date] => 2018-09-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 94264 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 61 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16125584 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17635199 [patent_doc_number] => 11345916 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-05-31 [patent_title] => Single stranded oligonucleotides inhibiting endocytosis [patent_app_type] => utility [patent_app_number] => 16/644151 [patent_app_country] => US [patent_app_date] => 2018-09-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 18 [patent_no_of_words] => 29899 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 51 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16644151 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16141963 [patent_doc_number] => 10704046 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-07-07 [patent_title] => Multimeric oligonucleotide compounds [patent_app_type] => utility [patent_app_number] => 16/118297 [patent_app_country] => US [patent_app_date] => 2018-08-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 45 [patent_figures_cnt] => 57 [patent_no_of_words] => 32133 [patent_no_of_claims] => 31 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 182 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16118297 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13622867 [patent_doc_number] => 20180362985 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-12-20 [patent_title] => UNA OLIGOMERS HAVING REDUCED OFF-TARGET EFFECTS IN GENE SILENCING [patent_app_type] => utility [patent_app_number] => 16/109231 [patent_app_country] => US [patent_app_date] => 2018-08-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8266 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -31 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16109231 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19242174 [patent_doc_number] => 12012596 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-06-18 [patent_title] => Target sequence specific alteration technology using nucleotide target recognition [patent_app_type] => utility [patent_app_number] => 16/640521 [patent_app_country] => US [patent_app_date] => 2018-08-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 14 [patent_no_of_words] => 12720 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 111 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16640521 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16238602 [patent_doc_number] => 20200255836 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-13 [patent_title] => NUCLEIC ACID APTAMER FOR INHIBITING ACTIVITY OF GENOME-EDITING ENZYME [patent_app_type] => utility [patent_app_number] => 16/639389 [patent_app_country] => US [patent_app_date] => 2018-08-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14642 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 143 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16639389 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16946658 [patent_doc_number] => 20210205349 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-08 [patent_title] => INHIBITION OF NGLY1 FOR THE TREATMENT OF CANCER [patent_app_type] => utility [patent_app_number] => 16/639027 [patent_app_country] => US [patent_app_date] => 2018-08-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31775 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16639027 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13590759 [patent_doc_number] => 20180346928 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-12-06 [patent_title] => LENTIVIRAL TRIPLEX DNA, AND VECTORS AND RECOMBINANT CELLS CONTAINING LENTIVIRAL TRIPLEX DNA [patent_app_type] => utility [patent_app_number] => 16/044451 [patent_app_country] => US [patent_app_date] => 2018-07-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16735 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16044451 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14214629 [patent_doc_number] => 20190119699 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-04-25 [patent_title] => LENTIVIRAL TRIPLEX DNA, AND VECTORS AND RECOMBINANT CELLS CONTAINING LENTIVIRAL TRIPLEX DNA [patent_app_type] => utility [patent_app_number] => 16/044462 [patent_app_country] => US [patent_app_date] => 2018-07-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16734 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16044462 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14407549 [patent_doc_number] => 20190169618 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-06-06 [patent_title] => NUCLEIC ACIDS AND METHODS FOR THE TREATMENT OF POMPE DISEASE [patent_app_type] => utility [patent_app_number] => 16/042714 [patent_app_country] => US [patent_app_date] => 2018-07-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16354 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16042714 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14132731 [patent_doc_number] => 20190100755 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-04-04 [patent_title] => OLIGONUCLEOTIDES FOR TREATING EXPANDED REPEAT DISEASES [patent_app_type] => utility [patent_app_number] => 16/038580 [patent_app_country] => US [patent_app_date] => 2018-07-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20267 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16038580 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14467773 [patent_doc_number] => 20190185529 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-06-20 [patent_title] => SIGNAL-SENSOR POLYNUCLEOTIDES FOR THE ALTERATION OF CELLULAR PHENOTYPES [patent_app_type] => utility [patent_app_number] => 16/036170 [patent_app_country] => US [patent_app_date] => 2018-07-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 158333 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16036170 [rel_patent_id] =>[rel_patent_doc_number] =>)